Net book value at 1 January
FX on acquisition
Effect of movements in exchange rates
Net book value at 31 December
The Group tests goodwill for impairment annually or more frequently if there are indications that goodwill might be impaired. For the purpose of the impairment testing, the Group operates as one segment, Biopharmaceuticals, and has one single cash-generating unit (CGU), which represents the lowest level at which the goodwill is monitored.
The recoverable amount of the CGU is determined based on the value-in-use calculations and the methodology applied for performing the impairment testing has not been modified compared to 2019.